Stem definition | Drug id | CAS RN |
---|---|---|
bradykinin receptors antagonists | 4186 | 130308-48-4 |
Dose | Unit | Route |
---|---|---|
30 | mg | P |
None
Date | Agency | Company | Orphan |
---|---|---|---|
Sept. 21, 2018 | PMDA | Shire Japan KK | |
July 11, 2008 | EMA | Shire Pharmaceuticals Ireland Limited | |
Aug. 25, 2011 | FDA | SHIRE ORPHAN THERAP |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Hereditary angioedema | 3339.90 | 35.01 | 528 | 2708 | 5725 | 53340105 |
Pharyngeal oedema | 246.28 | 35.01 | 72 | 3164 | 14541 | 53331289 |
Prescribed overdose | 210.40 | 35.01 | 63 | 3173 | 13796 | 53332034 |
Laryngeal oedema | 194.93 | 35.01 | 49 | 3187 | 5596 | 53340234 |
Inappropriate schedule of product administration | 137.81 | 35.01 | 74 | 3162 | 74804 | 53271026 |
No adverse event | 101.90 | 35.01 | 49 | 3187 | 39216 | 53306614 |
Injection site pain | 88.40 | 35.01 | 65 | 3171 | 113326 | 53232504 |
Swollen tongue | 55.02 | 35.01 | 30 | 3206 | 31050 | 53314780 |
Localised oedema | 50.79 | 35.01 | 17 | 3219 | 5292 | 53340538 |
Hospitalisation | 47.05 | 35.01 | 37 | 3199 | 70975 | 53274855 |
Device related infection | 45.97 | 35.01 | 24 | 3212 | 22762 | 53323068 |
Angioedema | 41.72 | 35.01 | 28 | 3208 | 42048 | 53303782 |
Poor venous access | 40.35 | 35.01 | 17 | 3219 | 9958 | 53335872 |
Injection site erythema | 38.20 | 35.01 | 34 | 3202 | 77215 | 53268615 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Hereditary angioedema | 1333.38 | 51.22 | 163 | 541 | 717 | 32512105 |
Injection site pain | 54.40 | 51.22 | 22 | 682 | 33036 | 32479786 |
Inappropriate schedule of product administration | 53.83 | 51.22 | 24 | 680 | 45801 | 32467021 |
Source | Code | Description |
---|---|---|
ATC | B06AC02 | BLOOD AND BLOOD FORMING ORGANS OTHER HEMATOLOGICAL AGENTS OTHER HEMATOLOGICAL AGENTS Drugs used in hereditary angioedema |
MeSH PA | D000700 | Analgesics |
MeSH PA | D018712 | Analgesics, Non-Narcotic |
MeSH PA | D000893 | Anti-Inflammatory Agents |
MeSH PA | D000894 | Anti-Inflammatory Agents, Non-Steroidal |
MeSH PA | D018501 | Antirheumatic Agents |
MeSH PA | D065094 | Bradykinin B2 Receptor Antagonists |
MeSH PA | D065168 | Bradykinin Receptor Antagonists |
MeSH PA | D051056 | Complement Inactivating Agents |
MeSH PA | D007155 | Immunologic Factors |
MeSH PA | D007166 | Immunosuppressive Agents |
MeSH PA | D018373 | Peripheral Nervous System Agents |
MeSH PA | D018689 | Sensory System Agents |
FDA MoA | N0000182964 | Bradykinin B2 Receptor Antagonists |
FDA EPC | N0000182965 | Bradykinin B2 Receptor Antagonist |
CHEBI has role | CHEBI:35530 | beta-adrenoceptor antagonists |
CHEBI has role | CHEBI:63175 | peptidomimetics |
CHEBI has role | CHEBI:68557 | bradykinin receptor antagonists |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Hereditary angioneurotic edema | indication | 82966003 | DOID:14735 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 3.3 | acidic |
pKa2 | 13.85 | acidic |
pKa3 | 12.18 | Basic |
pKa4 | 10.88 | Basic |
pKa5 | 10.16 | Basic |
pKa6 | 7.56 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
B2 bradykinin receptor | GPCR | ANTAGONIST | Ki | 10.22 | CHEMBL | CHEMBL | |||
B1 bradykinin receptor | GPCR | ANTAGONIST | Ki | 7 | IUPHAR | ||||
B2 bradykinin receptor | GPCR | Ki | 10.11 | CHEMBL | |||||
B2 bradykinin receptor | GPCR | Ki | 9.96 | CHEMBL | |||||
B2 bradykinin receptor | GPCR | ANTAGONIST | Ki | 9.60 | IUPHAR | ||||
B1 bradykinin receptor | GPCR | ANTAGONIST | Ki | 6.40 | IUPHAR |
ID | Source |
---|---|
4031108 | VUID |
N0000183562 | NUI |
D04492 | KEGG_DRUG |
138614-30-9 | SECONDARY_CAS_RN |
4031108 | VANDF |
C0246269 | UMLSCUI |
CHEBI:68556 | CHEBI |
CHEMBL2028850 | ChEMBL_ID |
CHEMBL2028852 | ChEMBL_ID |
DB06196 | DRUGBANK_ID |
C065679 | MESH_SUPPLEMENTAL_RECORD_UI |
667 | IUPHAR_LIGAND_ID |
6922 | INN_ID |
7PG89G35Q7 | UNII |
6918173 | PUBCHEM_CID |
1148138 | RXNORM |
160761 | MMSL |
320534 | MMSL |
d07393 | MMSL |
012894 | NDDF |
012895 | NDDF |
703834005 | SNOMEDCT_US |
703835006 | SNOMEDCT_US |
715582002 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Icatibant | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-3066 | INJECTION, SOLUTION | 10 mg | SUBCUTANEOUS | ANDA | 27 sections |
Icatibant | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24201-207 | INJECTION, SOLUTION | 30 mg | SUBCUTANEOUS | ANDA | 29 sections |
Icatibant | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54092-135 | INJECTION, SOLUTION | 30 mg | SUBCUTANEOUS | NDA authorized generic | 34 sections |
Firazyr | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54092-702 | INJECTION, SOLUTION | 30 mg | SUBCUTANEOUS | NDA | 34 sections |
ICATIBANT | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60505-6214 | INJECTION, SOLUTION | 30 mg | SUBCUTANEOUS | ANDA | 29 sections |
Icatibant | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-574 | INJECTION, SOLUTION | 10 mg | SUBCUTANEOUS | ANDA | 29 sections |
Icatibant | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68462-828 | INJECTION, SOLUTION | 30 mg | SUBCUTANEOUS | ANDA | 29 sections |
ICATIBANT | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69097-664 | INJECTION | 30 mg | SUBCUTANEOUS | ANDA | 25 sections |
SAJAZIR | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70709-013 | INJECTION | 30 mg | SUBCUTANEOUS | ANDA | 25 sections |
Icatibant | Human Prescription Drug Label | 1 | 71225-114 | INJECTION | 30 mg | SUBCUTANEOUS | ANDA | 26 sections |